Ideaya Biosciences saw significant new institutional investment, according to SEC filings reported on August 27, 2026. BlackRock Inc. acquired a new stake in the company, purchasing 8,893,260 shares, which represents about 10.12% ownership of the company. The total value of the investment was approximately $331.45 million.
In a separate filing, Deutsche Bank AG also reported a new position in Ideaya Biosciences during the second quarter. The bank purchased 93,844 shares, valued at roughly $3.50 million. These new investments follow a period of strong stock performance and a recent clinical collaboration with Genentech announced on August 19. The influx of capital from major financial institutions indicates a high level of confidence in the company's future prospects and drug pipeline.